Edition:
United Kingdom

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

4.91USD
20 Apr 2018
Change (% chg)

$0.07 (+1.45%)
Prev Close
$4.84
Open
$4.81
Day's High
$5.03
Day's Low
$4.81
Volume
155,623
Avg. Vol
301,863
52-wk High
$7.39
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES.IDERA PHARMACEUTICALS INC - ‍MERGER AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​.IDERA PHARMACEUTICALS INC - ROBERT INGRAM TO BE CHAIRMAN OF BOARD, VINCENT MILANO TO BE CEO OF COMBINED COMPANY.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF BIOCRYST COMMON STOCK WILL BE EXCHANGED FOR 0.50 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF IDERA COMMON STOCK WILL BE EXCHANGED FOR 0.20 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - ‍SIGNIFICANT STOCKHOLDER OF CO, BIOCRYST AGREED TO ENTER VOTING AND SUPPORT AGREEMENT AND HAS AGREED TO VOTE IN FAVOR OF DEAL​.IDERA PHARMACEUTICALS INC - AFTER DEAL BIOCRYST STOCKHOLDERS WILL OWN 51.6 PERCENT OF STOCK OF COMBINED COMPANY, CO'S STOCKHOLDERS TO OWN 48.4 PERCENT.IDERA PHARMACEUTICALS - COMBINED COMPANY, WHICH WILL BE RENAMED POST-CLOSING, WILL BE HEADQUARTERED AT CURRENT IDERA HEADQUARTERS.IDERA PHARMACEUTICALS INC - STOCK ISSUANCE IN MERGER IS EXPECTED TO BE TAX-FREE TO STOCKHOLDERS.  Full Article

BioCryst Pharma files for mixed shelf of up to $200 million‍​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - BioCryst Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing‍​.  Full Article

BioCryst Pharmaceuticals reports Q3 loss per share of $0.18
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - BioCryst Pharmaceuticals Inc ::Reports third quarter 2017 financial results.Q3 loss per share $0.18.Q3 revenue $8.8 million versus $7.8 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.6 million -- Thomson Reuters I/B/E/S.Expect to start single required phase 3 efficacy and long-term safety trials for BCX7353 in Q1 2018 ​.‍U.S. Orphan Drug Designation for BCX7353 received from FDA​.  Full Article

Biocryst Pharmaceuticals prices public offering of common stock
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Biocryst Pharmaceuticals Inc :Biocryst Pharmaceuticals prices public offering of common stock.Pricing of underwritten public offering of 15.5 million shares of common stock, offered at a price to public of $5.15 per share.  Full Article

D. E. Shaw & Co L.P. reports passive stake of 5.1 pct in Biocryst Pharmaceuticals as of Aug. 11
Monday, 22 Aug 2016 

Biocryst Pharmaceuticals Inc :D. E. Shaw & Co., L.P. reports a passive stake of 5.1 percent in Biocryst Pharmaceuticals Inc as of August 11, 2016 - Sec filing.  Full Article

Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals
Wednesday, 17 Aug 2016 

Biocryst Pharmaceuticals Inc : Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals Inc - SEC filing .Baker Bros' Felix Baker's stake of about 11.1 million shares in Biocryst Pharmaceuticals includes 75,000 shares of co's common stock underlying options.  Full Article

Felix Baker reports stake of 14.99 pct in BioCryst Pharmaceuticals
Tuesday, 16 Aug 2016 

BioCryst Pharmaceuticals Inc : Felix J. Baker reports a stake of 14.99% in BioCryst Pharmaceuticals Inc as of Aug 12 - SEC filing .Felix J. Baker reported a stake of 20.5% in BioCryst Pharmaceuticals Inc as of Feb 4 - SEC filing.  Full Article

Deerfield Mgmt Reports 6.64 pct passive stake in BioCryst Pharmaceuticals
Friday, 12 Aug 2016 

Biocryst Pharmaceuticals Inc :Deerfield Mgmt, L.P. Reports 6.64 pct passive stake in BioCryst Pharmaceuticals as of August 12, 2016 - SEC Filing.  Full Article

Biocryst Q2 loss per share $0.22
Thursday, 4 Aug 2016 

BioCryst Pharmaceuticals Inc : BioCryst reports second quarter 2016 financial results . Q2 revenue $4.8 million versus I/B/E/S view $3.9 million . Q2 loss per share $0.22 . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Expects 2016 net operating cash use to be in range of $55 to $75 million . Says expect initial data from apex-1 to be available by year end 2016 .Expects 2016 operating expenses to be in range of $78 to $98 million.  Full Article